Skip to main content
SpringerLink
Log in

Prognostic role of circulating microRNA-21 in cancers: evidence from a meta-analysis

  • Research Article
  • Published:
Tumor Biology

Abstract

Circulating microRNAs (miRNAs) exhibit altered expression in patients with cancer and could be considered as potential prognostic biomarker of cancer. Here, we performed a meta-analysis to summarize all the results from available studies, aiming to analyze the prognostic role of circulating microRNA-21 (miR-21) in human cancers. Eligible studies were identified from PubMed and EMBASE through multiple search strategies. We extracted and estimated the hazard ratios (HRs) for overall survival (OS), which compared the high and low expression levels of circulating miR-21 in patients with a variety of carcinomas. Pooled HRs and 95 % confidence intervals (CIs) were calculated. Eleven studies with a total of 1,224 patients with various carcinomas were included this meta-analysis. For OS, higher circulating miR-21expression could significantly predict worse outcome with the pooled HR of 2.11 (95 % CI 1.36–3.26, P = 0.0009). The subgroup analysis suggested that the elevated circulating miR-21 expression was correlated with worse OS in Asian population with the pooled HR of 2.36 (95 % CI 1.61–3.48, P < 0.0001) and digestive system cancers with the pooled HR of 2.19 (95 % CI 1.01–4.75, P = 0.05). The present meta-analysis suggests that circulating miR-21 expression is associated with poor survival in patients with cancer and could be a prognostic biomarker for those patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  2. Bartel DP. Micrornas: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.

    Article  CAS  PubMed  Google Scholar 

  3. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–54.

    Article  CAS  PubMed  Google Scholar 

  4. Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2010;10:297–308.

    Article  CAS  PubMed  Google Scholar 

  5. Nana-Sinkam P, Croce CM. MicroRNAs in diagnosis and prognosis in cancer: what does the future hold? Pharmacogenomics. 2010;11:667–9.

    Article  CAS  PubMed  Google Scholar 

  6. Madhavan D, Cuk K, Burwinkel B, Yang R. Cancer diagnosis and prognosis decoded by blood-based circulating microrna signatures. Front Genet. 2013;4:116.

    PubMed Central  CAS  PubMed  Google Scholar 

  7. Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett. 2013;329:125–36.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Komatsu S, Ichikawa D, Takeshita H, Konishi H, Nagata H, Hirajima S, et al. Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma. Expert Opin Biol Ther. 2012;12 Suppl 1:S53–9.

    Article  CAS  PubMed  Google Scholar 

  9. Komatsu S, Ichikawa D, Tsujiura M, Konishi H, Takeshita H, Nagata H, et al. Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. Anticancer Res. 2013;33:271–6.

    PubMed  Google Scholar 

  10. Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem. 2012;58:610–8.

    Article  CAS  PubMed  Google Scholar 

  11. Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, Wang YK, et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol. 2012;29:618–26.

    Article  CAS  PubMed  Google Scholar 

  12. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105:849–59.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Wang ZX, Bian HB, Wang JR, Cheng ZX, Wang KM, De W. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol. 2011;104:847–51.

    Article  CAS  PubMed  Google Scholar 

  14. Xu YZ, Xi QH, Ge WL, Zhang XQ. Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pac J Cancer Prev. 2013;14:1057–60.

    Article  PubMed  Google Scholar 

  15. Yuan J, Chen L, Chen X, Sun W, Zhou X. Identification of serum microRNA-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma. J Int Med Res. 2012;40:2090–7.

    Article  CAS  PubMed  Google Scholar 

  16. Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y, et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol. 2013;34:2175–81.

    Article  CAS  PubMed  Google Scholar 

  17. Menendez P, Padilla D, Villarejo P, Palomino T, Nieto P, Menendez JM, et al. Prognostic implications of serum microRNA-21 in colorectal cancer. J Surg Oncol. 2013;108:369–73.

    Article  CAS  PubMed  Google Scholar 

  18. Song J, Bai Z, Zhang J, Meng H, Cai J, Deng W, et al. Serum microRNA-21 levels are related to tumor size in gastric cancer patients but cannot predict prognosis. Oncol Lett. 2013;6:1733–7.

    PubMed Central  CAS  PubMed  Google Scholar 

  19. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (moose) group. JAMA. 2000;283:2008–12.

    Article  CAS  PubMed  Google Scholar 

  20. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.

    Article  CAS  PubMed  Google Scholar 

  21. Chen W, Wang H, Chen H, Liu S, Lu H, Kong D, et al. Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in chinese population. Eur J Haematol. 2014.

  22. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672–5.

    Article  PubMed  Google Scholar 

  23. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mrnas. Nature. 2005;433:769–73.

    Article  CAS  PubMed  Google Scholar 

  24. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006;25:6188–96.

    Article  CAS  PubMed  Google Scholar 

  25. Zhang B, Pan X, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302:1–12.

    Article  CAS  PubMed  Google Scholar 

  26. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, et al. Circulating plasma miR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011;6:e17745.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251:499–505.

    Article  PubMed  Google Scholar 

  28. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127:118–26.

    Article  CAS  PubMed  Google Scholar 

  29. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58:1375–81.

    Article  CAS  PubMed  Google Scholar 

  30. Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010;25:1674–80.

    Article  CAS  PubMed  Google Scholar 

  31. Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. 2012;36:e61–7.

    Article  CAS  PubMed  Google Scholar 

  32. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–70.

    Article  CAS  PubMed  Google Scholar 

  34. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007;120:1046–54.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008;14:2690–5.

    Article  CAS  PubMed  Google Scholar 

  36. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 2012;138:1659–66.

    Article  CAS  PubMed  Google Scholar 

  38. Krichevsky AM, Gabriely G. Mir-21: a small multi-faceted RNA. J Cell Mol Med. 2009;13:39–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene. 2008;27:4373–9.

    Article  CAS  PubMed  Google Scholar 

  40. Yang CH, Yue J, Pfeffer SR, Handorf CR, Pfeffer LM. Microrna miR-21 regulates the metastatic behavior of B16 melanoma cells. J Biol Chem. 2011;286:39172–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27:2128–36.

    Article  CAS  PubMed  Google Scholar 

  42. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microrna miR-21 in breast cancer cells. J Biol Chem. 2008;283:1026–33.

    Article  CAS  PubMed  Google Scholar 

  43. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the pten tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–58.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Si ML, Zhu S, Wu H, Lu Z, Wu F. Mo YY: miR-21-mediated tumor growth. Oncogene. 2007;26:2799–803.

    Article  CAS  PubMed  Google Scholar 

  45. Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko Jr RJ, et al. MicroRNA-21 negatively regulates Cdc25a and cell cycle progression in colon cancer cells. Cancer Res. 2009;69:8157–65.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol. 2008;28:5369–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 2007;282:14328–36.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200000, People’s Republic of China

    Yinlong Yang

  2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200000, People’s Republic of China

    Yinlong Yang

  3. Department of Breast Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, Yunnan, People’s Republic of China

    Jinxian Qian

  4. Department of Surgical Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, People’s Republic of China

    Yizuo Chen & Yifei Pan

Authors
  1. Yinlong Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jinxian Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yizuo Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yifei Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yinlong Yang or Yifei Pan.

Additional information

Yinlong Yang and Jinxian Qian contributed equally to this work and are co-first authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, Y., Qian, J., Chen, Y. et al. Prognostic role of circulating microRNA-21 in cancers: evidence from a meta-analysis. Tumor Biol. 35, 6365–6371 (2014). https://doi.org/10.1007/s13277-014-1846-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1846-8

Keywords

Search

Navigation